Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:6263
Name inflammatory breast carcinoma
Definition A breast adenocarcinoma that is characterized by the clinical appearance of inflammation, with edema and redness of the breast due to pathologic plugging of the dermal lymphatics of the breast with tumor emboli.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer breast carcinoma breast adenocarcinoma inflammatory breast carcinoma


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02411656 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy Active, not recruiting USA 0
NCT02971748 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy Active, not recruiting USA 0
NCT03202316 Phase II Atezolizumab + Cobimetinib + Eribulin Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer Active, not recruiting USA 0
NCT03598257 Phase II Olaparib Radiation Therapy With or Without Olaparib in Treating Participants With Inflammatory Breast Cancer Recruiting USA | CAN 1
NCT03742986 Phase II Cyclophosphamide + Doxorubicin Nivolumab + Paclitaxel Docetaxel + Nivolumab + Pertuzumab + Trastuzumab Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) Completed USA 0
NCT05093387 Phase I Carboplatin + Pembrolizumab + SGT-53 SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer Withdrawn USA 0
NCT05243641 Phase Ib/II Capmatinib + Neratinib Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER2 and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test Recruiting USA 0
NCT05795101 Phase II Durvalumab + Trastuzumab deruxtecan TRUDI: TDXD+Durva in HER2+/Low IBC (TRUDI) Recruiting USA 0